Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B6f884945cac69192872d3b4972a93fe6> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B6f884945cac69192872d3b4972a93fe6 NCIT_P378 "NCI" @default.
- B6f884945cac69192872d3b4972a93fe6 type Axiom @default.
- B6f884945cac69192872d3b4972a93fe6 annotatedProperty IAO_0000115 @default.
- B6f884945cac69192872d3b4972a93fe6 annotatedSource NCIT_C169756 @default.
- B6f884945cac69192872d3b4972a93fe6 annotatedTarget "The maleate salt form of abivertinib, an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, abivertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR." @default.